Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast - 2034

Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast - 2034

Key Highlights

DelveInsight’s analyst projects that the Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD) in the 7MM were ~33.3 million in 2023 and these cases are going to increase during the forecast period (2024–2034). This increase in growth can be attributed to growing awareness, ultimately leading to an increase in the diagnosed prevalence of COPD.

Analyst projected that approximately 55% of the Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD) in the 7MM were in the United States. Furthermore In 2023, the EU4 and the UK collectively represented nearly 13.8 million diagnosed prevalent cases of COPD.

The Total Diagnosed Prevalent Cases of COPD in the US was found to be nearly 18.5 million in 2023, while Japan accounted for nearly 3% of the Total Diagnosed Prevalent Cases of COPD in the 7MM in 2023.

DelveInsight’s “Chronic Obstructive Pulmonary Disease (COPD) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology of Chronic Obstructive Pulmonary Disease in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Chronic Obstructive Pulmonary Disease Understanding

Chronic Obstructive Pulmonary Disease (COPD) is a prevalent condition that can be prevented and managed, marked by persistent respiratory symptoms and restricted airflow resulting from airway and/or alveolar irregularities, typically stemming from prolonged exposure to harmful particles or gases. The development of COPD entails complex pathological processes, leading to different subgroups with specific traits and progression trajectories. This diversity results in differing frequencies of exacerbations, limitations in airflow, and declines in lung function. Challenges in managing COPD arise from the complexity of addressing these varied characteristics effectively.

Chronic Obstructive Pulmonary Disease Diagnosis

The diagnosis of COPD typically involves a combination of clinical assessment, imaging techniques, and laboratory tests, including examination of removed corneas. Presently, methods such as slit lamp examination, specular microscopy, corneal thickness measurement, and confocal microscopy are utilized for COPD detection. However, there exists a significant gap in medical needs to enhance the sensitivity of early-stage testing. Despite the development of various tools like deep learning algorithms and advanced imaging techniques such as Scheimpflug tomography and anterior segment optical coherence tomography (AS-OCT) to improve early disease diagnosis, there remains a necessity to enhance the availability and accessibility of these image analysis tools for early detection, monitoring disease progression, and facilitating tailored therapeutic interventions.

Further details related to diagnosis are provided in the report…

Chronic Obstructive Pulmonary Disease Epidemiology

For the purpose of designing the patient-based model for Chronic Obstructive Pulmonary Disease (COPD), the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of COPD, Gender-specific Diagnosed Prevalent Cases of COPD, Age-specific Diagnosed Prevalent Cases of COPD, Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

DelveInsight’s analyst estimate that approximately 33.3 million Diagnosed Prevalent Cases of COPD were found in 2023 in the 7MM.

The United States exhibited the highest diagnosed prevalent population of COPD, as compared to other 7MM countries. As per DelveInsight’s estimations, the Total Diagnosed Prevalent Cases of COPD in the US was around 18.1 million in 2023 and is projected to increase during the forecast period owing to the increasing prevalence of smoking, improved diagnosis and increasing awareness among the patient population.

Analyst estimates that, the Total Diagnosed Prevalent Cases of COPD in EU4 and the UK were found to be ~13.6 million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of COPD cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.

The estimates show the Total Diagnosed Prevalent Cases of COPD in Japan was found to be around 0.9 million in 2023, which is estimated to increase by 2034 at a significant CAGR.

The Gender-specific Cases of COPD in the 7MM were ~18.2 million for females and ~15.1 million for males in 2023 and are expected to increase within the forecast period (2024–2034). The increased prevalence in females is likely due to a combination of factors, including genetics, environmental factors, and healthcare inequalities, among others.

The Age-specific Cases of COPD were categorized into 18-44 years, 45-54 years, 55-64 years, 65-74 years, and 75+ years. The higher number of cases (~4.8 million) was accounted for by the 55-64 year age group in 2023 in the US.

The Diagnosed Prevalence of COPD Based on Severity of Airflow Limitation was categorized into GOLD (Global Initiative for Chronic Obstructive Lung Disease) 1–4. According to DelveInsight estimates, a higher number of patients were estimated in the GOLD 2 category, with approximately 6.4 million cases in 2023 in EU4 and the UK.

The GOLD guidelines combine FEV1 reduction, dyspnea, and exacerbation history to classify patients with COPD into Groups A–D. According to estimations by DelveInsight’s analysts, the Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History were higher in the GOLD A category in the US with nearly 9.8 million cases in 2023.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Holy Cross Hospital, USA, Hospital Universitario de Guadalajara, Spain, Instituto de Investigación Sanitaria Gregorio Marañón, Spain, Tokyo Women's Medical University, Japan, The University of Sheffield, UK, University of Rome, Italy, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Chronic Obstructive Pulmonary Disease, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Chronic Obstructive Pulmonary Disease Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Diagnosed Prevalent Cases of COPD

Gender-specific Diagnosed Prevalent Cases of COPD

Age-specific Diagnosed Prevalent Cases of COPD

Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation

Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History

Chronic Obstructive Pulmonary Disease Report Key Strengths

11 years Forecast

The 7MM Coverage

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation

Chronic Obstructive Pulmonary Disease Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Chronic Obstructive Pulmonary Disease? What will be the growth opportunities across the 7MM concerning the patient population of Chronic Obstructive Pulmonary Disease?

What is the historical and forecasted Chronic Obstructive Pulmonary Disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the diagnosed prevalent cases of COPD in Japan lower than the US?

Which country has a high patient share for COPD?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Chronic Obstructive Pulmonary Disease prevalence cases in varying geographies over the coming years.

A detailed overview of Gender and Age Grade-specific diagnosed prevalence of COPD, along with diagnosed prevalence of COPD Based on severity of airflow limitation and diagnosed prevalence of COPD based on symptoms and exacerbation history.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Chronic Obstructive Pulmonary Disease Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Chronic Obstructive Pulmonary Disease (COPD) cases in 2023?

The highest cases of Chronic Obstructive Pulmonary Disease was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Chronic Obstructive Pulmonary Disease (COPD) cases in 2023?

The highest cases of Chronic Obstructive Pulmonary Disease were found in the US among the 7MM in 2023.